Danielle D. Irvine
Associate
Danielle Dudding Irvine has experience representing clients in antitrust litigation, regulation, and compliance matters across a variety of industries. She has provided counsel and analysis of proposed mergers and acquisitions, Hart-Scott-Rodino (HSR) and pre-merger filing notifications, and Second Request compliance. Danielle maintains an active pro bono practice, focusing primarily on wrongful convictions.
Danielle D. Irvine
Associate
Danielle Dudding Irvine has experience representing clients in antitrust litigation, regulation, and compliance matters across a variety of industries. She has provided counsel and analysis of proposed mergers and acquisitions, Hart-Scott-Rodino (HSR) and pre-merger filing notifications, and Second Request compliance. Danielle maintains an active pro bono practice, focusing primarily on wrongful convictions.
Prior to joining Axinn, Danielle practiced in the litigation and antitrust departments of a national law firm, where she advised clients facing complex civil and criminal litigation and investigations.
Danielle earned her JD at Vanderbilt University Law School, where she served as the executive editor of the Vanderbilt Journal of Entertainment & Technology Law. While in law school, Danielle interned at the International Criminal Tribunal for the former Yugoslavia.
She holds a BA in International Studies from Southern Methodist University, where she was admitted to Phi Beta Kappa.
Experience
- Represented Ball Corporation in its $5.6 billion sale of its aerospace division to BAE Systems.
- Represented McKesson Corporation, a leading diversified healthcare services company, in a joint venture combining McKesson’s U.S. Oncology Research (USOR) and HCA Healthcare Inc.’s (HCA) Sarah Cannon Research Institute (SCRI).
- Represented individuals successfully in DOJ no-poach and bid-rigging investigations.
- Represented Alvogen in an antitrust and patent infringement litigation regarding Indivior’s opioid dependency treatment drug Suboxone® Film. The court denied a motion for summary judgment directed to Alvogen’s antitrust claim directed to exclusionary rebating practices. The case was the first of its kind in the pharmaceutical industry where the antitrust plaintiff was able to avoid summary judgment.
- Served as co-counsel in a pro bono wrongful conviction proceeding, resulting in the client’s exoneration.
Honors
- Mid-South Super Lawyers, “Rising Star” (2021)
- Memphis Business Journal, Best of the Bar Honoree – Ace Associate (2020)
- Empire State Counsel Honoree for pro bono service (2022)
Education
- JD – Order of the Coif, Vanderbilt University Law School (2016)
- BA, International Studies, magna cum laude – Southern Methodist University (2012)
Admissions
- New York
- Tennessee
- U.S. Court of Appeals for the Sixth Circuit
- U.S. District Court Eastern District of New York
- U.S. District Court Southern District of New York
- U.S. District Court Western District of Tennessee
- U.S. District Court Middle District of Tennessee
- U.S. District Court Eastern District of Tennessee
Quotes
Axinn proves to have not just the necessary knowledge and skill to handle complex and sophisticated matters, but the depth of experience to anticipate unforeseen hurdles.
Chambers USA
News & Insights
News & Insights
United States: Cartels
Byline Articles
Antitrust
Axinn Successfully Obtains Order Affirming Dismissal of Federal Discrimination Claims Against the American Bankers Association
Deals & Cases
Litigation & Trials
Axinn Secures Antitrust Clearance for Ball Corporation’s $5.6B Sale to BAE Systems
Deals & Cases
Antitrust
How Bass Berry Helped Free 3 Wrongfully Convicted Men
Media Mentions
Antitrust
Axinn Pro Bono Work Helps Secure Release of Wrongfully Incarcerated Individual
News
Antitrust
Six Axinn Attorneys Named to Empire State Counsel Program
News
Antitrust
Axinn Advises Ball Corporation in its $5.6 Billion Sale of its Aerospace Division to BAE Systems
News
Antitrust
Antitrust Cartel Leniency and Sentencing Handbook
Publications
Antitrust
Axinn Advises McKesson on Joint Venture with HCA Healthcare
News
Antitrust